New study from MD Anderson and BridgeBio's Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer

(University of Texas M. D. Anderson Cancer Center) New preclinical research from MD Anderson and Navire finds a novel drug targeting SHP2 can overcome multiple paths of therapeutic resistance in lung cancer. Navire will launch a clinical trial of SHP2 inhibitors by the end of 2020.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news